Who We Are

Who are ClonMedica?

The consumer division of Clonmel Healthcare was rebranded in early 2007 under the name ClonMedica. This was the next logical step in our corporate brand development strategy, following the rebranding of the Clonmel Healthcare Ethical business division a short time previously. The ClonMedica range of products comprises of original, stand-alone, international brands that serve the mother and baby, pain relief and health supplement sectors. ClonMedica now represents almost 20% of Clonmel healthcare’s business in Ireland and it is planned that in the future this division will play a stronger, more strategic role in the overall business.

Who are Clonmel Healthcare?

In 2006 Clonmel Healthcare embarked on a brand redevelopment strategy following the findings of a major customer research report. In early 2007 the new corporate identity was launched. The new distinctive brand mark represents Clonmel Healthcare’s core values of quality, customer service and dynamism and retains the strength of our heritage and strong link to our Irish roots. Clonmel Healthcare currently has a large portfolio of products covering three distinct business units; Prescription medicines, Speciality medicines and the ClonMedica Consumer Division. Our prescription products cover a wide range of therapeutic areas including CNS, cardiovascular, Nsaid, gastro-intestinal and anti-infectives. Within the Special Products Division we have medicines for the treatment of Parkinson’s disease, Testosterone Deficiency Syndrome and the management of diabetes. The ClonMedica product range focuses on three main areas; women’s and babies health, skincare and health supplements. All of our alternative brand prescription medicines undergo rigorous and stringent control procedures as required by the Irish Medicines Board, and they are bioequivalent to the originator product. Clonmel Healthcare is committed to providing less expensive, quality medicines to the Irish market.

Key Message

  • To provide innovative and highest quality medicines with an economic advantage.
  • To continue to introduce to Ireland speciality pharmaceutical products for specific needs.
  • To develop a closer relationship with the health professionals and the public alike through the use of continuing education.
Awards 2014